

A Sulfone-mediated Synthesis of (+)-Preussin

John J. Caldwell, Donald Craig,* Stephen P. East


Centre for Chemical Synthesis, Department of Chemistry, Imperial College of Science, Technology and Medicine, London SW7 2AY, UK
Fax +44(20)75945868; E-mail: d.craig@ic.ac.uk

Received 23 July 2001

Abstract: The synthesis of the antifungal pyrrolidine (+)-preussin is described, utilising the 5-*endo-trig* cyclisation of a vinylic sulfone generated in situ to give the requisite pyrrolidine nucleus.

Key words: cyclisation, natural products, stereoselectivity, sulfones, total synthesis


We have been evaluating the utility of 5-*endo-trig* cyclisations of sulfonyl-substituted amines and alcohols for the construction of heterocycles including pyrrolidines,¹ and reported quite recently the application of this methodology to the synthesis of the indolizidine alkaloid (+)-monomorphine **1** (Figure). The final stage in this synthesis was the reductive removal of the phenylsulfonyl moiety, and we were keen to exploit further the diverse reactivity of this versatile functional group.² It occurred to us that hydroxy-substituted pyrrolidines should be accessible from the 5-*endo-trig* cyclisation products simply by oxidation of the sulfone-stabilised carbanion³ and subsequent reduction of the product ketone. Isolated and characterised in 1988,⁴ the disubstituted hydroxypyrrolidine antifungal agent (+)-preussin **2** has been the subject of a number of synthetic approaches,⁵ and the all-*syn* disposition of the pyrrolidine substituents made it an ideal target upon which to evaluate the proposed extension of our methodology. We report herein the sulfone-mediated total synthesis of **2** (Figure).



Figure


Our initial retrosynthetic analysis of (+)-preussin was adapted from the synthesis of (+)-monomorphine **1** (Scheme 1). We had found⁶ subsequent to the monomorphine work that *N*-2-(trimethylsilyl)ethylsulfonyl-protected (*N*-SES-protected) vinylic sulfone-containing amines such as **6** could be synthesised in a one-pot olefination procedure by combination of aldehydes with the adducts of (phenylsulfonyl)methane and aziridines, such as **5**. This work had demonstrated further that sulfonamides re-

lated to **6** underwent desulfonylation and cyclisation in situ upon treatment with *n*-Bu₄NF, giving pyrrolidines analogous to **4**. For the synthesis of **2**, precursor ketone **3** would be made by oxidation of the sulfone-stabilised carbanion generated from the *N*-methyl derivative of **4**. In particular, it was felt that the use of readily enolisable phenylacetaldehyde as the coupling partner in the preparation of substrate **6** would provide a rigorous test of the applicability of this one-pot method. Precursor aziridine **7**, formally derived from a D-amino acid would be accessed from L-serine **8** by reversing the relative oxidation levels at C1 and C3.




Scheme 1

Aziridine **7** was made using an adaptation of the work of Rapoport (Scheme 2).⁷ Thus, addition of excess *n*-octylmagnesium iodide-*n*-butyllithium to *N*-tosyl-L-serine⁸ provided ketone **9**, which was deoxygenated to give the *N*-protected amino alcohol **10** by conversion into the dithiane under standard conditions and subsequent treatment with Raney nickel. This was cyclodehydrated by treatment with TsCl-KOH⁹ to provide the corresponding *N*-tosylaziridine **11** in near-quantitative yield. Finally, replacement of the *N*-tosyl protecting group with the SES function¹⁰ was achieved by reductive desulfonylation followed by re-sulfonylation using SESCl-DMAP in the presence of base, giving **7** in 12% overall yield from L-serine (39% from ketone **9**). The instability of the SES protecting group towards the excess organometallic reagent used in the conversion **8**→**9** precluded its incorporation from the outset, necessitating the desulfonylation-resulfonylation sequence.



Scheme 2 Reagents and conditions: (i) 2 M NaOH, TsCl, H₂O, EtOAc; (ii) *n*-BuLi (2 equiv), H₁₇C₈MgI (4 equiv), THF, Et₂O; (iii) HS(CH₂)₃SH, BF₃·OEt₂, CH₂Cl₂; (iv) Ni(*R*), EtOH, reflux; (v) KOH, TsCl, THF, r.t.; (vi) Na, naphthalene, THF, –78 °C; (vii) SESCl, DMAP, Et₃N, CH₂Cl₂, 0 °C


Aziridine **7** reacted smoothly with the lithio-anion of (phenylsulfonyl)methane to give the expected adduct **5**. Double deprotonation of **5** followed by sequential addition of phenylacetaldehyde and benzoyl chloride under the conditions which had been successful with less readily enolisable coupling partners⁶ gave the allylic sulfone **12** in low yield, with virtually none of the desired vinylic sulfone **6** (Scheme 3).



Scheme 3 Reagents and conditions: (i) *n*-BuLi, THF, TMEDA, –78 °C, add **7**, –78 °C→r.t., 89%; (ii) *n*-BuLi, THF, –78 °C then phenylacetaldehyde, then BzCl

Though unwelcome, these observations appeared to be fully consistent with the greater thermodynamic stability of allylic sulfones compared with their vinylic isomers and the acidity of the phenylacetaldehyde α -protons. It occurred to us that **12** might itself be a substrate for 5-*endo-trig* cyclisation, since the fluoride-containing medium should be sufficiently basic to promote equilibration of unsaturated sulfone isomers **6** and **12**. This modified approach appeared especially attractive because substrate **12** could in principle be made simply by combining the appropriate allylic sulfone anion with **7**, thereby making the synthesis more convergent. In the event, reaction of the lithio-anion of (*E*)-3-phenyl-1-(phenylsulfonyl)-2-propene¹¹ **13** with **7** gave directly a diastereomeric mixture of the adducts **12** in excellent yield. Treatment of **12** with excess *n*-Bu₄NF gave pyrrolidine **4** in high yield as a single stereoisomer, having the 2,3-*anti*, 2,5-*syn* stereochemistry observed previously in 5-*endo-trig* cyclisations of this type.^{1b,c} Although **4** could have been formed by direct 5-*exo-trig* cyclisation of **12**, it seems unlikely that an unsubstituted phenyl group would confer sufficient electrophilicity on the styryl linkage for cyclisation to occur. Also, although substrate **12** was an epimeric mixture at the sulfone centre, product **4** was a single diastereomer. Therefore, for 5-*exo-trig* cyclisation to have oc-

curred either (i) the two epimers of **12** cyclised with mutually opposite stereochemistry relative to the phenylsulfonyl group, and epimerisation of the sulfonyl stereo-centre in one of the isomers occurred post-cyclisation, or (ii) one of the two epimers of **12** was unreactive, equilibrating with the reactive isomer prior to stereoselective cyclisation; both these scenarios seem relatively unlikely given the facility of 5-*endo-trig* cyclisation in the absence of the competing 5-*exo* pathway.^{1b,c} Compound **4** was next subjected to reductive amination⁵ⁱ to give the *N*-methyl derivative **14**. Reaction of the derived lithio-anion with TMSOOTMS¹² provided ketone **3**^{5e} which was reduced to give (+)-preussin **2**. Compound **2** prepared in this way had spectral characteristics identical with those reported for the natural product.^{4,5} The completion of the synthesis of **2** is depicted in Scheme 4.¹³



Scheme 4 Reagents and conditions: (i) add *n*-BuLi to **13**, THF, TMEDA, –78 °C, then add **7**, –78 °C→r.t.; (ii) TBAF (15 equiv), THF, reflux, 38 h; (iii) HCHO (aq), NaCNBH₃, AcOH, MeCN; (iv) *n*-BuLi, THF, then TMSOOTMS; (v) LiAlH₄, THF, –78 °C

In summary, a 12-step synthesis of (+)-preussin **2** from (*E*)-3-phenyl-1-(phenylsulfonyl)-2-propene and L-serine has been achieved. During the course of this investigation a new mode of 5-*endo-trig* cyclisation has been uncovered in which the requisite vinylic sulfone is generated in situ from a more readily available allylic precursor, and this renders the approach more convergent. We are currently evaluating the generality of this isomerisation–cyclisation process, and are assessing its utility in the synthesis of more complex pyrrolidine-containing targets. The results of these investigations will be reported in due course.

Acknowledgement

We thank EPSRC and F. G. Hoffmann-La Roche for financial support of this research.

References and Notes

- (1) (a) Craig, D.; Ikin, N. J.; Mathews, N.; Smith, A. M. *Tetrahedron* **1999**, *55*, 13471. (b) Craig, D.; Jones, P. S.; Rowlands, G. J. *Synlett* **1997**, 1423. (c) Berry, M. B.; Craig, D.; Jones, P. S.; Rowlands, G. J. *Chem. Commun.* **1997**, 2141.

- (2) *Sulphones in Organic Synthesis*; Simpkins, N. S., Ed.; Pergamon: Oxford, **1993**.
- (3) Najera, C.; Yus, M. *Tetrahedron* **1999**, *55*, 10547.
- (4) (a) Scharztz, R. E.; Liesch, J.; Hensens, O.; Zitano, L.; Honeycutt, S.; Garrity, G.; Fromtling, R. A.; Onishi, J.; Monaghan, R. *J. Antibiot.* **1988**, 1744. (b) Johnson, J. H.; Phillipson, D. W.; Kahle, A. D. *J. Antibiot.* **1989**, 1184.
- (5) (a) Pak, C. S.; Lee, G. H. *J. Org. Chem.* **1991**, *56*, 1128. (b) Shimazaki, M.; Okazaki, F.; Nakajima, F.; Ishikawa, T.; Ohta, A. *Heterocycles* **1993**, *36*, 1823. (c) McGrane, P. L.; Livinghouse, T. *J. Am. Chem. Soc.* **1993**, *115*, 11485. (d) Overhand, M.; Hecht, S. M. *J. Org. Chem.* **1994**, *59*, 4721. (e) Deng, W.; Overman, L. E. *J. Am. Chem. Soc.* **1994**, *116*, 11241. (f) Yoda, H.; Yamazaki, H.; Takabe, K. *Tetrahedron: Asymmetry* **1996**, *7*, 373. (g) Beier, C.; Schaumann, E. *Synthesis* **1997**, 1296. (h) deArmas, P.; Garcia-Tellado, F.; Marrero-Tellado, J. J.; Robles, J. *Tetrahedron Lett.* **1998**, *39*, 131. (i) Kanazawa, A.; Gillet, S.; Delair, P.; Greene, A. E. *J. Org. Chem.* **1998**, *63*, 4660. (j) Bach, T.; Brummerhop, H. *Angew. Chem. Int. Ed.* **1998**, *37*, 3400. (k) Verma, R.; Ghosh, S. K. *J. Chem. Soc., Perkin Trans. 1* **1999**, 265. (l) Veeresa, G.; Datta, A. *Tetrahedron* **1998**, *54*, 15673. (m) Lee, K.-Y.; Kim, Y.-H.; Oh, C.-Y.; Ham, W.-H. *Org. Lett.* **2000**, 4041. (n) Okue, M.; Watanabe, H.; Kitahara, T. *Tetrahedron* **2001**, *57*, 4107.
- (6) Craig, D.; East, S. P. unpublished observations.
- (7) Maurer, P. J.; Takahata, H.; Rapoport, H. *J. Am. Chem. Soc.* **1984**, *106*, 1095; all yields reported herein refer to isolated, pure materials which had ^1H and ^{13}C NMR, IR and high-resolution MS characteristics in accord with the proposed structures.
- (8) Hofmann, K.; Jöhl, A.; Furlenmeier, A. E.; Kappeler, H. *J. Am. Chem. Soc.*; **1956**, *79*, 1636.
- (9) The method used was an adaptation of a procedure for *N*-Boc aziridination using Boc_2O -KOH in Et_2O :Wessig, P.; Schwarz, J. *Synlett* **1997**, 893.
- (10) Weinreb, S. M.; Demko, D. M.; Lessen, T. A.; Demers, J. P. *Tetrahedron Lett.* **1986**, *27*, 2099.
- (11) Pyne, S. G.; David, D. M.; Dong, Z. *Tetrahedron Lett.* **1998**, *39*, 8499.
- (12) Hwu, J. R. *J. Org. Chem.* **1983**, *48*, 4433.
- (13) Preparation of **4**.
A solution of **12** (640 mg, 1.08 mmol) in TBAF (16.22 mL of a 1 M solution in THF, 16.22 mmol, 15 equiv) was heated under reflux under nitrogen for 38 h. MeOH (5 mL) was added to the cooled solution followed by water (50 mL). The mixture was extracted with EtOAc (2×50 mL) and the combined organic layers dried (MgSO_4), and concentrated

under reduced pressure. Chromatographic purification (SiO_2 ; 30% EtOAc-petrol) of the crude product gave [2*S*,3*R*,5*R*]-2-benzyl-3-phenylsulfonyl-5-nonylpyrrolidine **4** (360 mg, 0.842 mmol, 78%) as a clear oil; $[\alpha]_{\text{D}}^{20}$ -9.6 (*c* 4.16, CHCl_3); ν_{max} (film) 3336, 3084, 3066, 3032, 3003, 2981, 2954, 2924, 2848, 2731, 2669, 1603, 1585, 1495, 1446, 1406, 1377, 1304, 1176, 1145, 1086, 1028 cm^{-1} ; δ_{H} (300 MHz) 7.97–7.91 (2 H, m, Ar), 7.73–7.57 (3 H, m, Ar), 7.32–7.10 (5 H, m, Ar), 3.76 (1 H, ddd, *J* 9.0, 7.0, 3.5 Hz, H-2), 3.36 (1 H, ddd, *J* 10.5, 7.0, 3.5 Hz, H-3), 3.08 (1 H, dq, *J* 10.0, 6.5 Hz, H-5), 2.82 (1 H, dd, *J* 13.5, 3.5 Hz, CHHPh), 2.64 (1 H, dd, *J* 13.5, 9.0 Hz, CHHPh), 2.40 (1 H, ddd, *J* 13.5, 6.5, 3.5 Hz, H-4), 1.88 (1 H, br s, N-H), 1.57 (1 H, dt, *J* 13.5, 10.0 Hz, H-4), 1.49–1.15 (16 H, m, $(\text{CH}_2)_8$), 0.89 (3 H, t, *J* 6.5 Hz, CH_3); δ_{C} (75 MHz) 139.0, 138.4, 134.0, 129.6, 129.4, 128.8, 128.7, 126.8, 67.3, 60.7, 58.4, 41.8, 35.9, 34.3, 32.0, 29.9, 29.7 (2 C), 29.5, 27.2, 22.8, 14.3; *m/z* (CI) 428 $[\text{MH}]^+$ (Found: $[\text{MH}]^+$, 428.2615; $\text{C}_{26}\text{H}_{37}\text{NO}_2\text{S}$ requires $[\text{MH}]^+$, 428.2623).

Preparation of **3**.

To a stirred solution of sulfone **14** (164 mg, 0.371 mmol) in THF (2 mL) at -78°C under nitrogen was added *n*-BuLi (165 μL of a 2.7 M solution in hexanes, 0.446 mmol, 1.2 equiv) to give a pale yellow solution. After 15 min a solution of TMSOOTMS (86 mg, 0.483 mmol, 1.3 equiv) in THF (0.5 mL) was added via syringe. The solution was allowed to attain r.t. over 2 h, and then stirred at r.t. for a further 15 h. After quenching with saturated aqueous NaHCO_3 (15 mL) the mixture was extracted with EtOAc (3×10 mL). The combined organic layers were dried (MgSO_4) and concentrated under reduced pressure. The resulting crude product was purified by chromatography (SiO_2 ; 20% EtOAc-petrol) to give recovered starting material **14** (55 mg, 34%) and [2*S*,5*R*]-2-benzyl-1-methyl-5-nonyl-3-oxo-pyrrolidine **3** (57 mg, 49%, 74% based on recovered **14**) as a pale yellow oil; $[\alpha]_{\text{D}}^{20}$ -97.9 (*c* 1.43, CHCl_3); ν_{max} (film) 3055, 2956, 2927, 2856, 1751, 1411, 1379, 1265, 1151, 1115, 1082 cm^{-1} ; δ_{H} (300 MHz) 7.32–7.15 (5 H, m, Ph), 3.08 (1 H, dd, *J* 14.0, 4.5 Hz, CHHPh), 2.87 (1 H, dd, *J* 14.0, 5.0 Hz, CHHPh), 2.78 (1 H, distorted t, H-2), 2.55–2.44 (1 H, m, H-5), 2.41 (1 H, dd, *J* 17.5, 6.0 Hz, H-4), 2.33 (3 H, s, NMe), 1.79 (1 H, dd, *J* 18.0, 10.5 Hz, H-4), 1.40–1.10 (16 H, m, $(\text{CH}_2)_8$), 0.91 (3 H, t, *J* 6.5 Hz, CH_2CH_3); δ_{C} (75 MHz) 215.0, 138.7, 129.9, 128.2, 126.3, 74.5, 62.6, 42.9, 39.4, 36.1, 33.1, 32.1, 30.0, 29.7 (2 C), 29.5, 25.8, 22.9, 14.3; *m/z* (CI) 306 $[\text{MH}]^+$ (Found: $[\text{MH}]^+$, 316.2637; $\text{C}_{21}\text{H}_{33}\text{NO}$ requires $[\text{MH}]^+$, 316.2640).